Skip to main content
Therma Bright Inc. logo

Therma Bright Inc. — Investor Relations & Filings

Ticker · THRM ISIN · CA8834262070 LEI · 529900PN7P0GSORO2174 TSXV Manufacturing
Filings indexed 525 across all filing types
Latest filing 2024-07-18 Regulatory Filings
Country CA Canada
Listing TSXV THRM

About Therma Bright Inc.

https://www.thermabright.com/

Therma Bright Inc. is a medical technology company that develops, acquires, and markets proprietary diagnostic and medical device technologies for the consumer and institutional healthcare sectors. The company's portfolio addresses key areas including pain management, circulation, diagnostics, and critical care. Core products and development projects include Venowave, a medical device designed to boost circulation and prevent blood clots; the Digital Cough Test (DCT), an AI-powered application developed with AI4LYF for rapid, non-invasive detection of respiratory diseases; and the PREVA™ clot retriever, developed with Inretio for enhanced thrombectomy procedures in ischemic stroke treatment. Furthermore, Therma Bright is advancing inhaled statin therapy in partnership with InVixa for the treatment of COVID-19 pneumonia and Acute Respiratory Distress Syndrome (ARDS).

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2024-07-18 English
News release - English.pdf
Regulatory Filings
2024-07-18 English
Material change report - English.pdf
Regulatory Filings
2024-07-04 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a market update from Therma Bright Inc. dated Q2 2024. It discusses a private placement capital raise, regulatory updates (HCPCS and CPT codes), product development progress, investment updates, and strategic review progress. The content focuses on business updates, capital raising, and strategic initiatives rather than detailed financial statements or earnings results. It is not a full annual or interim report, nor an earnings release or call transcript. The document also includes information about stock options granted under a rolling stock option plan, which relates to capital/financing activities. Given the emphasis on capital raising, strategic review, and business updates, this fits best under Capital/Financing Update (CAP). The document length (8267 characters) and detailed content support this classification with high confidence.
2024-07-03 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-06-28 English
Interim MD&A - English.pdf
Regulatory Filings
2024-06-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.